(Q31925591)

5 July 2017

1 reference

title

Efficacy of cyclooxygenase-2-specific inhibitors (English)

1 reference

5 July 2017

Cannon GW

1

1 reference

5 July 2017

Breedveld FC

series ordinal

2

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

American Journal of Medicine

5 July 2017

published in

1 reference

5 July 2017

volume

110 Suppl 3A

1 reference

5 July 2017

page(s)

6S-12S

1 reference

Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Mechanism of action of nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Mechanism of action of aspirin-like drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900681-1

10.1016/S0002-9343(00)00681-1

7 January 2021

Identifiers

DOI

1 reference

5 July 2017

1 reference